5 July 2019

1 year of Oncode: building the Launching Platform

Public summary of the Oncode Annual Report 2018

Elize Brolsma

Elize Brolsma

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.

Oncode is proud to present the public summary of its first Annual Report, which showcases highlights of the first year of Oncode. We invite you to read about how we set out to build the foundations of our Research Institute. An institute which fosters a multidisciplinary research environment. Where researchers are provided with access to world class infrastructure, technologies, training, support teams and the financial means to support high-risk research projects. In 2018 we focused on building the launching platform for our future activities. We launched key scientific programmes, started up a dedicated valorization team, hosted events, built an online community and shaped a dedicated patient engagement programme.

In short, the report shows you the many ways we are working on our mission: outsmarting cancer, impacting lives.

The Oncode Management Board 

Click here to read the full report

Other News

Picture1
Absence of stem cells in pancreas changes view on pancreatic cancer
New research by Oncode Investigator Louis Vermeulen and co-investigator Maarten Bijlsma shows that there are no stem cells in the pancreas. These unexpected findings potentially have major implications for pancreatic cancer research, since stem cells are often at the root of tumor development. This research was published today in the leading journal Cell Stem Cell.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>

Support Programme
Antibodies with a mission: what the Utrecht Monoclonal Antibody Facility (UMab) can do for you
As part of the Infrastructure and Technology programme, Oncode started a collaborative project together with Oncode Investigator Linde Meyaard (UMCU) and Jeanette Leusen (head of the Utrecht Monoclonal Antibody Facility (UMab)) with the goal of being able to offer Oncode Investigators the opportunity to produce high quality antibodies (targeted against membrane proteins). Oncode is now looking to fund a total of 4 Oncode Investigators to develop monoclonal antibodies potentially suited for clinical applications in oncology, directed against their membrane target of choice.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>

Oncode Icons Square research strategy copy
Oncode collaboration results in a new mathematical method that can predict cancer survival based on genetic changes
As cancer survival rates vary widely, Oncode Researcher Daniel Miedema from Oncode Investigator Louis Vermeulen’s lab (Amsterdam UMC), in collaboration with the teams of Oncode Investigators Hugo Snippert (UMC Utrecht) and Geert Kops (Hubrecht Institute) has developed a mathematical method to predict survival based on genetic changes in cancer. The results of this study are now published in Nature Communications.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>